This is a preview of subscription content, log in via an institution to check access.
References
Rodero MP, Crow YJ. Type I interferon-mediated monogenic autoinflammation: the type I interferonopathies, a conceptual overview. J Exp Med. 2016;213(12):2527–38.
Crow YJ, Chase DS, Lowenstein Schmidt J, Szynkiewicz M, Forte GM, Gornall HL, et al. Characterization of human disease phenotypes associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR, and IFIH1. Am J Med Genet A. 2015;167A(2):296–312.
Rice GI, Forte GM, Szynkiewicz M, et al. Assessment of interferon-related biomarkers in Aicardi-Goutières syndrome associated with mutations in TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, and ADAR: a case-control study. Lancet Neurol. 2013;12(12):1159–69.
Pizzi S, Sertic S, Orcesi S, Cereda C, Bianchi M, Jackson AP, et al. Reduction of hRNase H2 activity in Aicardi Goutières syndrome cells leads to replication stress and genome instability. Hum Mol Genet. 2015;24(3):649–58.
Rice GI, Melki I, Frémond ML, Briggs TA, Rodero MP, Kitabayashi N, et al. Assessment of type I interferon signaling in pediatric inflammatory disease. J Clin Immunol. 2017;37(2):123–32.
Günther C, Kind B, Reijns MA, et al. Defective removal of ribonucleotides from DNA promotes systemic autoimmunity. J Clin Invest. 2015;125(1):413–24.
Bursztejn AC, Briggs TA, del Toro Duany Y, Anderson BH, O'Sullivan J, Williams SG, et al. Unusual cutaneous features associated with a heterozygous gain-of-function mutation in IFIH1: overlap between Aicardi-Goutières and Singleton-Merten syndromes. Br J Dermatol. 2015;173(6):1505–13.
Rutsch F, MacDougall M, Lu C, et al. A specific IFIH1 gain-of-function mutation causes Singleton-Merten Syndrome. Am J Hum Genet. 2015;96(2):275–82.
Funding
This report presents independent research funded by the National Institute for Health Research (NIHR) (NIHR Transitional Research Fellowship, Dr. Tracy Briggs, TRF-2016-09-002) and supported by the NIHR Manchester Biomedical Research Centre.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
With research consent (REC reference 17/SC/0026). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health.
Key message
Type I interferonopathies, including RNASEH2B mutations, should be considered in adults with severe digital ischemia.
Conflict of Interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Briggs, T.A., Paul, A., Rice, G. et al. RNASEH2B Related Adult-Onset Interferonopathy. J Clin Immunol 39, 620–622 (2019). https://doi.org/10.1007/s10875-019-00673-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10875-019-00673-w